Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment
Authors:
- Peter HajekPHPeter Hajek
- Serena TonstadSTSerena Tonstad
- 3 August 2009
- Vol. 104 (9) , 1597-1602
Abstract
Aim While older behavioural and pharmacological approaches to preventing relapse to smoking show little efficacy, a recent randomized trial of an extended course of varenicline reported positive results. In this secondary analysis, trial data were examined to see whether smokers who manage to achieve abstinence only later in the original course of treatment are more likely to benefit from having the course extended.Methods A total of 1208 patients abstinent for at least the last week of 12 weeks' treatment with varenicline were randomized to 3 months continued varenicline or placebo. Overall, 44% of the 12‐week abstainers were abstinent from the target quit date (TQD), while the rest stopped smoking later. We examined the relationship between quit pattern and the varenicline versus placebo difference in continuous abstinence rates at week 52 and contributions of baseline patient characteristics.Results With increasing delay in initial quitting, 12‐month success rates declined. Participants who had their last cigarette at week 11 of open‐label treatment had quit rates at 52 weeks of 5.7% compared with 54.9% in those who last smoked in week 1 [odds ratio (OR) 20.3 (6.3, 65.9); P < 0.0001]. Patients who failed to initiate abstinence in the first week benefited more from extended treatment than patients continuously abstinent from week 1 [OR 1.7 (1.2, 2.4); P = 0.0015 versus OR 1.1 (0.8, 1.5); P = 0.6995, respectively; with the interaction of the quit pattern with treatment effect reaching borderline significance (P = 0.0494)]. No other patient characteristics were related to treatment effect.Conclusions Compared with smokers who quit smoking on their TQD, those who have an initial delay in achieving sustained abstinence have increased risk of relapse even several months later, and may be more likely to benefit from extended treatment with varenicline.Keywords
This publication has 15 references indexed in Scilit:
- Evaluating the validities of different DSM‐IV‐based conceptual constructs of tobacco dependence*Addiction, 2008
- The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trialCurrent Medical Research and Opinion, 2008
- A comparison of the Fagerström Test for Nicotine Dependence and smoking prevalence across countriesAddiction, 2008
- Varenicline in the routine treatment of tobacco dependence: a pre–post comparison with nicotine replacement therapy and an evaluation in those with mental illnessAddiction, 2007
- Time to first cigarette in the morning as an index of ability to quit smoking: Implications for nicotine dependenceNicotine & Tobacco Research, 2007
- A Self-Administered Questionnaire to Measure Dependence on Cigarettes: The Cigarette Dependence ScaleNeuropsychopharmacology, 2003
- Higher dosage nicotine patches increase one‐year smoking cessation rates: results from the European CEASE trialEuropean Respiratory Journal, 1999
- First lapses to smoking: Within-subjects analysis of real-time reports.Journal of Consulting and Clinical Psychology, 1996
- Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HSIDrug and Alcohol Dependence, 1994
- The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance QuestionnaireBritish Journal of Addiction, 1991